NYSEAMERICAN:AZTR Azitra (AZTR) Stock Price, News & Analysis $0.80 -0.01 (-0.87%) As of 03:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Azitra Stock (NYSEAMERICAN:AZTR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Azitra alerts:Sign Up Key Stats Today's Range$0.78▼$0.8250-Day Range$0.75▼$1.6852-Week Range$0.70▼$4.44Volume151,355 shsAverage Volume1.45 million shsMarket Capitalization$2.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem. The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance. By delivering live commensal organisms directly to affected skin regions, Azitra seeks to restore healthy barrier function and reduce inflammation without relying on conventional small-molecule or biologic drug approaches. Founded in 2018, Azitra is traded on the NYSE American under the symbol AZTR. Its research and development operations combine microbiology, formulation science and translational dermatology, and the company’s clinical trials are conducted primarily in North America. Azitra has pursued collaborations with academic and medical centers to support its pipeline advancement. Azitra’s leadership team brings together expertise in microbiome research, dermatology and pharmaceutical development, guiding the company toward regulatory milestones and strategic partnerships. With a mission to harness the therapeutic potential of the skin microbiome, Azitra aims to offer novel, targeted treatments for patients with chronic skin diseases.AI Generated. May Contain Errors. Read More Azitra Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreAZTR MarketRank™: Azitra scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Azitra. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Azitra are expected to grow in the coming year, from ($2.78) to ($0.95) per share.Price to Book Value per Share RatioAzitra has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Azitra's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted30.00% of the float of Azitra has been sold short.Short Interest Ratio / Days to CoverAzitra has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Azitra has recently increased by 1,032.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAzitra does not currently pay a dividend.Dividend GrowthAzitra does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted30.00% of the float of Azitra has been sold short.Short Interest Ratio / Days to CoverAzitra has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Azitra has recently increased by 1,032.69%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News SentimentN/A News SentimentAzitra has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Azitra this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for AZTR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Azitra to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Azitra insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.25% of the stock of Azitra is held by insiders.Percentage Held by InstitutionsOnly 11.16% of the stock of Azitra is held by institutions.Read more about Azitra's insider trading history. Receive AZTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Azitra and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AZTR Stock News HeadlinesAzitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | prnewswire.comAzitra Inc Modifies Agreement with Alumni CapitalAugust 29, 2025 | tipranks.comREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.September 16 at 2:00 AM | Paradigm Press (Ad)Why Is Azitra (AZTR) Stock Soaring TodayAugust 28, 2025 | uk.finance.yahoo.comAzitra doses first patient in Phase 1/2 clinical trial of ATR04-484August 28, 2025 | msn.comAzitra shares surge after first patient receives ATR04-484 in Phase 1/2 trialAugust 27, 2025 | msn.comAzitra stock soars after first patient dosed in Phase 1/2 trialAugust 27, 2025 | za.investing.comAzitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated RashAugust 27, 2025 | prnewswire.comSee More Headlines AZTR Stock Analysis - Frequently Asked Questions How have AZTR shares performed this year? Azitra's stock was trading at $2.9624 at the beginning of 2025. Since then, AZTR shares have decreased by 72.7% and is now trading at $0.8090. How were Azitra's earnings last quarter? Azitra, Inc. (NYSEAMERICAN:AZTR) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.20) by $2.06. When did Azitra's stock split? Azitra's stock reverse split on Friday, August 22nd 2025.The 100-666 reverse split was announced on Monday, August 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 15 shares after the split. How do I buy shares of Azitra? Shares of AZTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Azitra own? Based on aggregate information from My MarketBeat watchlists, some other companies that Azitra investors own include NVIDIA (NVDA), Broadcom (AVGO), Tesla (TSLA), Advanced Micro Devices (AMD), CrowdStrike (CRWD), FedEx (FDX) and Intel (INTC). Company Calendar Last Earnings11/12/2024Today9/16/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:AZTR CIK1701478 Webazitrainc.com Phone203-646-6446FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.97 million Net MarginsN/A Pretax Margin-113,662.50% Return on Equity-183.57% Return on Assets-138.65% Debt Debt-to-Equity RatioN/A Current Ratio1.24 Quick Ratio1.24 Sales & Book Value Annual Sales$10 thousand Price / Sales285.58 Cash FlowN/A Price / Cash FlowN/A Book Value$4.97 per share Price / Book0.16Miscellaneous Outstanding Shares3,530,000Free Float3,517,000Market Cap$2.86 million OptionableNot Optionable Beta-1.61 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSEAMERICAN:AZTR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Azitra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Azitra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.